DoW Breast Cancer, Clinical Research Extension Award
Funds extension of breast cancer clinical studies by continuing data collection, follow-up, and analysis for eligible applicants, with required consumer advocate involvement.
⚑ Must address at least one FY26 BCRP overarching challenge or justify exception. · Research team must include two or more breast cancer consumer advocates. · Partnering PI option requires pre-application from Initiating PI only, but both PIs must submit full applications; missing any linked submission may trigger administrative withdrawal.
This is a breast cancer clinical research extension award, centered on biomedical/clinical trial follow-up and patient data collection. IPPRA’s strengths are social-behavioral risk, policy, education, and emergency/weather research, so this is not their program and would be an implausible PI-level fit.
JUDGED AGAINST THE ROSTER'S PUBLICATION DOSSIER · GPT-5.4-MINI · 2026-09-04
Unit fits — one characterization, each unit's own rules
| IPPRA | 58 good | peripheral portfolio topic: public_health; signature methods: community engaged; social/behavioral work is minor; funds evaluation research; biomedical core — IPPRA health lane is communication/crisis/policy (capped); clinical-trial/biomedical core — IPPRA angle is policy/community (capped) |
| Physical Sciences & Engineering (demo) | 40 partial | technical depth: substantial; funds evaluation research (capped) |
| Tom Love Innovation Hub | 15 none | deep-tech content; no commercialization signal |
Description
Summary: The fiscal year 2026 (FY26) Breast Cancer Research Program (BCRP) Clinical Research Extension Award supports research that extends the data collection, follow-up, and analysis of breast cancer clinical studies. The intent of this award mechanism is to increase the clinically relevant impact of breast cancer patient participation in clinical studies by addressing the knowledge lost due to early trial termination, limited patient follow-up, or suboptimal sample and/or data collection and analysis. All applications must address at least one of the FY26 BCRP overarching challenges or provide adequate justification for exception.
Distinctive Features:
• The research team must include two or more breast cancer consumer advocates.
• This funding mechanism allows for a single Principal Investigator (PI), or two partnering PIs referred to as the Initiating PI and the Partnering PI. For the Partnering PI Option (PPIO), only the Initiating PI will submit a pre-application, but both PIs will need to submit at the full application stage. Be advised, failure to submit all associated (Initiating and Partnering PI) applications by the deadline may result in administrative withdrawal.
Apply
View on Grants.gov → CONTACT: Danielle Reckley Grantor <help@eBRAP.org>
Proposal brief SEE AN EXAMPLE →
A one-page internal memo: fit assessment, submission requirements, document scaffold, and next steps dated back from the deadline — tailored to your project idea if you add one.
Proposal shell · Department of Defense (BAA-style) conventions SEE A DOD EXAMPLE →
Funder-faithful document skeletons — Department of Defense (BAA-style)'s document set with section headings, page limits, reviewer guidance, and writing prompts; add a project idea to get [DRAFT] starter bullets. Download as .md for Word or Overleaf.